An engineered prodrug selectively suppresses β-lactam resistant bacteria in a mixed microbial setting

Author:

Duda Addison M.ORCID,Ma Helena R.,Villalobos César A.,Kuhn Sophia A.,He Katherine,Seay Sarah R.,Jackson Abigail C.,Suh Christine M.,Puccio Elena A.,Anderson Deverick J.,Fowler Vance G.,You Lingchong,Franz Katherine J.ORCID

Abstract

AbstractThe rise of β-lactam resistance necessitates new strategies to combat bacterial infections. We purposefully engineered the β-lactam prodrug AcephPT to exploit β-lactamase activity to selectively suppress resistant bacteria producing extended-spectrum-β-lactamases (ESBLs). Selective targeting of resistant bacteria requires avoiding interaction with penicillin-binding proteins, the conventional targets of β-lactam antibiotics, while maintaining recognition by ESBLs to activate AcephPT only in resistant cells. Computational approaches provide a rationale for structural modifications to the prodrug to achieve this biased activity. We show AcephPT selectively suppresses gram-negative ESBL-producing bacteria in clonal populations and in mixed microbial cultures, with effective selectivity for both lab strains and clinical isolates expressing ESBLs. Time-course NMR experiments confirm hydrolytic activation of AcephPT exclusively by ESBL-producing bacteria. In mixed microbial cultures, AcephPT suppresses proliferation of ESBL-producing strains while sustaining growth of β-lactamase-non-producing bacteria, highlighting its potential to combat β-lactam resistance while promoting antimicrobial stewardship.Abstract Figure

Publisher

Cold Spring Harbor Laboratory

Reference38 articles.

1. β-Lactams and β-Lactamase Inhibitors: An Overview

2. Epidemiology of β-Lactamase-Producing Pathogens

3. ; for the Antibacterial Resistance Leadership Group;Confronting Antimicrobial Resistance Together. Am. J. Physiol. Lung Cell Mol,2022

4. Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threats in the United States, 2019; Centers for Disease Control and Prevention (U.S.), 2019.

5. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis;The Lancet,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3